Regenerative Medicines Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Regenerative Medicines Market – By Product Type (Biologically derived materials, Genetically engineered materials, Synthetic materials, Pharmaceuticals, Others), By Technology (Gene therapy, Small molecules and biologicals, Cell therapy, Tissue engineering), By Application (Dermatology, Cardiovascular, Orthopaedic, Oncology, Wound healing, Neurology, Ophthalmology, Others), By End user (Hospitals, Clinics, Research laboratories, Others) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Regenerative Medicines Market size was valued USD 9.8 billion in 2021 and expected to reach a value of USD 26.4 billion by 2028, witnessing a CAGR of 15.2% during the forecast period 2022-2028. Regenerative medicines are those, which replace, repair, and regenerate organs and tissues affected due to the disease, injury, and natural aging process. Regenerative medicines have a wide range of applications and used in the neurodegenerative, cardiovascular, orthopedic, and dermatological disorders. Regenerative medicines also include the possibility of growing organs and tissues in the laboratory and implanted them when the body cannot heal itself. The major biomedical approaches in regenerative medicines are stem cells which have an ability of differentiation and proliferation of cells. Increase in the prevalence of genetic disorders, rise in funding from public and private sectors for the R&D activities in regenerative medicines, increase in healthcare expenditure, and various products in the pipeline are expected to fuel the regenerative medicines market over the forecast period. Furthermore, technological advancements in stem cell therapy and nanotechnology, growing need of orthopedic surgeries, an increase in awareness about regenerative medicines among key stakeholders might propel the market growth over the forecast period. However, stringent regulatory policies for regenerative medicines approval, high cost for the treatment, and ethical issues might hamper the regenerative medicines market over the forecast timeframe.

Regenerative Medicines Market

MARKET SUMMARY
-
14.6%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 15.2%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Regenerative Medicines Market

  • The report on global regenerative medicines market gives historical, current and future market sizes (US$ Mn) based on the product type, by technology, application and end user and region.
  • regenerative medicines market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Market Key Players
  • Osiris Therapeutics, Inc
  • Organogenesis Inc.
  • NuVasive, Inc.
  • Hitachi, Ltd.
  • Allergan
Growth

Regenerative Medicines Market

Regenerative medicines market is growing at a significant CAGR owing to increase in the prevalence of chronic diseases such as cancer, cardiovascular, and neurological disorders. Increase in the number of organ transplantation and surgical procedures is expected to drive the market growth over the forecast period. Acquisitions, mergers, and collaborations between the companies, and introduction technologically advanced products might increase the competitor’s revenue share in the regenerative medicines market. For instance, in December 2016, Allergan has acquired Lifecell for expanding its product portfolio in a hernia and breast reduction surgeries. Similarly, in June 2014, Aastrom Biosciences acquired the Sanofi’s cell therapy and regenerative business segment for strengthening its cell therapy portfolio. Moreover, in March 2016, Hitachi Chemical and Caladrius Biosciences PCT inked an agreement for the manufacturing of regenerative medicine cells.


North-America Got Significant Share

Regenerative Medicines Market

Geographically, regenerative medicines market is segmented into North America, Latin America, Europe, Middle East & Africa, and Asia Pacific. North America expected to hold a major share in global market owing to technological advancements in the newer products, the presence of major key players, adoption of regenerative medicines and increase in funding from public and private sectors in the region. Europe regenerative medicines market is growing at the significant rate over the forecast period owing to increase in the prevalence of cancer and other chronic diseases, a rise in focus on the R&D activities, and technological developments in the region. However, Asia Pacific expected to exhibit lucrative growth owing to collaborations between the organizations for the regenerative medicines development, favorable regulatory guidelines for clinical adoption in Japan & China, an increase in the R&D investment expected to boost the regenerative market growth over the forecast timeframe.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

NOTABLE MARKET DEVELOPMENTS

  • In August 2017, organizations namely, Association of Biotechnology Led Enterprise (ABLE, India) and Forum for Innovative Regenerative Medicine (FIRM, Japan) have collaborated for the advancement and commercialization of regenerative medicine in India and Japan
  • In March 2017, Organogenesis Inc. acquired NuTech Medical for widening its portfolio in beyond the wound care

Key

Key Findings OF THE REPORT

Regenerative Medicines Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content


Report

Company Profile

  • Osiris Therapeutics, Inc. (U.S.)
  • Organogenesis Inc. (U.S.)
  • NuVasive, Inc. (U.S.)
  • Acelity (KCI Concepts) (U.S.)
  • Stryker Corporation (U.S.)
  • Integra LifeSciences (U.S.)
  • Hitachi, Ltd. (Japan)
  • Vericel Corporation (U.S.)
  • C.R. Bard (U.S.)
  • Allergan (Ireland)
  • Caladrius Biosciences (U.S.)

Description

Regenerative Medicines Market size was valued USD 9.8 billion in 2021 and expected to reach a value of USD 26.4 billion by 2028, witnessing a CAGR of 15.2% during the forecast period 2022-2028. Regenerative medicines are those, which replace, repair, and regenerate organs and tissues affected due to the disease, injury, and natural aging process. Regenerative medicines have a wide range of applications and used in the neurodegenerative, cardiovascular, orthopedic, and dermatological disorders. Regenerative medicines also include the possibility of growing organs and tissues in the laboratory and implanted them when the body cannot heal itself. The major biomedical approaches in regenerative medicines are stem cells which have an ability of differentiation and proliferation of cells. Increase in the prevalence of genetic disorders, rise in funding from public and private sectors for the R&D activities in regenerative medicines, increase in healthcare expenditure, and various products in the pipeline are expected to fuel the regenerative medicines market over the forecast period. Furthermore, technological advancements in stem cell therapy and nanotechnology, growing need of orthopedic surgeries, an increase in awareness about regenerative medicines among key stakeholders might propel the market growth over the forecast period. However, stringent regulatory policies for regenerative medicines approval, high cost for the treatment, and ethical issues might hamper the regenerative medicines market over the forecast timeframe.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX